GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial

The company progresses its mRNA-based candidate just under a month after Moderna won FDA approval for the first seasonal flu mRNA vaccine. The company progresses its mRNA-based candidate just under a month after Moderna won FDA approval for the first seasonal flu mRNA vaccine. GSK hopes to initiate the Phase III trial on its mRNA-based influenza vaccine in September 2026. Credit: Thurtthai Chaiyakid / Shutterstock.com. GSK’s seasonal, mRNA-based influenza vaccine is progressing to a Phase III study after securing a safety and efficacy win in a mid-stage trial – potentially poising it to become a market competitor to Moderna’s newly…

Source: Clinical Trials Arena